HLA-DMA: A Potential Drug Target and Biomarker (G3108)

Target Name: HLA-DMA

NCBI ID: G3108

HLA-DMA

HLA-DMA: A Potential Drug Target and Biomarker

HLA-DMA (HLA-Donor-MHC-DMA) is a protein that is expressed in the major histocompatibility complex (MHC) and is involved in the presentation of antigens to T-cells. It is a 22-kDa glycoprotein that is derived from the MHC class I region and consists of a core region that contains a single glycophosphorylated serine residue and a cytoplasmic tail that is involved in cell-surface antigen presentation.

HLA-DMA is a potential drug target because of its involvement in the immune response and its expression in various tissues, including the spleen, thymus, spleen-derived immune cells, and peripheral blood T-cells. It is also a biomarker for various diseases, including systemic lupus erythematosus (SLE), a chronic autoimmune disease.

Drugs that target HLA-DMA have the potential to treat various diseases, including SLE, autoimmune disorders, and cancer. In this article, we will discuss the potential mechanisms of HLA-DMA as a drug target and biomarker, as well as the current research on this protein and its potential therapeutic applications.

Mechanisms of HLA-DMA as a Drug Target

HLA-DMA is involved in the presentation of antigens to T-cells, which is a critical step in the immune response. It is expressed in various tissues and is involved in the development of T-cells, including CD4+ and CD8+ T-cells. HLA-DMA is also involved in regulating the activation and proliferation of T-cells.

Targeting HLA-DMA with drugs has the potential to treat various diseases, including SLE, an autoimmune disease that affects millions of people worldwide. SLE is characterized by the production of autoantibodies that target the body's own tissues and can cause inflammation, pain, and damage to various organs.

One approach to targeting HLA-DMA is to use small molecules that can inhibit its activity as a presentation agent for antigens. Small molecules that inhibit HLA-DMA function have been shown to be effective in treating SLE by reducing the production of autoantibodies and slowing the progression of disease.

Mechanisms of HLA-DMA as a Biomarker

HLA-DMA is involved in the presentation of antigens to T-cells, which is a critical step in the immune response. It is expressed in various tissues and is involved in the development of T-cells, including CD4+ and CD8+ T-cells. HLA-DMA is also involved in regulating the activation and proliferation of T-cells.

HLA-DMA is also involved in the regulation of immune cell function and has been shown to play a role in the development and maintenance of autoimmune diseases. For example, HLA-DMA has been shown to be involved in the development of rheumatoid arthritis (RA) (14) and in the regulation of the response of T-cells to antigens.

Use of HLA-DMA as a biomarker for disease diagnosis and monitoring has the potential to improve the accuracy and effectiveness of immunological assessments in the diagnosis and treatment of autoimmune diseases. For example, HLA-DMA has been shown to be a reliable biomarker for the diagnosis of RA (17) and has been used to monitor the effectiveness of anti-rheumatic drugs in treating RA.

Current Research on HLA-DMA

HLA-DMA is an important protein that is involved in the immune response and has been shown to play a critical role in the development and maintenance of autoimmune diseases. The study of HLA-DMA is ongoing, and there is a growing interest in its potential as a drug target and biomarker.

HLA-DMA has been shown to be involved in the regulation of T

Protein Name: Major Histocompatibility Complex, Class II, DM Alpha

Functions: Plays a critical role in catalyzing the release of class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules and freeing the peptide binding site for acquisition of antigenic peptides. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO

The "HLA-DMA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DMA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets